Overview of CRISPR
CRISPR represents a groundbreaking technology that is revolutionizing lives and making significant strides in the healthcare sector. CRISPR, an acronym for “Clustered Regularly Interspaced Short Palindromic Repeats,” is present in prokaryotes—tiny, single-celled entities lacking organelles. These patterns are located within the genomes of prokaryotes, which bundle a cell’s DNA.
Serving as a gene editing instrument, CRISPR is employed to alter particular sections of DNA to address critical health issues. Its notable utility is in its ability to protect the body against viral pathogens by integrating the invading DNA into its genome, thereby equipping it to identify and eliminate the virus in subsequent exposures. Remarkably, CRISPR stands out from other gene editing techniques due to its enhanced accuracy and simpler programming, facilitating a more straightforward sequence modification. Unlike other gene-editing approaches that usually depend on a single protein, CRISPR utilizes RNA-guided targeting alongside the Cas9 enzyme.
Mechanism of CRISPR
CRISPR operates by leveraging a natural defense system found in bacteria, which enables them to detect and eliminate viral threats. Upon the invasion of a viral particle into a bacterial cell (a prokaryote), the bacterium retains a fragment of the invader’s DNA within its genome as a type of genetic “memory.” This capability allows the bacterium to identify and react more efficiently to subsequent infections.
In the realm of gene editing, this mechanism is adapted using two primary components: the Cas9 enzyme, which acts like molecular scissors to sever DNA, and guide RNA, which instructs Cas9 to find the specific genetic sequence that requires modification. After the target DNA is cleaved, the cell’s inherent repair processes come into play, enabling researchers to make alterations to the genetic sequence.
In contrast to previous methods that depended on difficult-to-reprogram proteins, CRISPR’s RNA-guided framework is more adaptable, simpler to design, and exceedingly precise. This ease of use and precision has facilitated the application of CRISPR across fields such as medicine, agriculture, production, and microbiology—such as designing microbes to enhance product yields. Nevertheless, as this article delves into, increasing capabilities bring forth heightened ethical dilemmas, particularly concerning germline editing and genetic upgrades.
The First Patient to Receive Personalized CRISPR Treatment
In February 2025, the globe witnessed its inaugural personalized CRISPR treatment for an infant named KJ, aimed at addressing a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme crucial for converting ammonia (which is generated during protein breakdown) into urea. A group headed by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia pioneered this treatment following extensive research in gene editing and cooperation with other medical professionals.
Their research concentrated on disorders impacting the urea cycle, leading to toxic levels of ammonia that harm organs like the brain and liver. They customized the treatment specifically for KJ’s variant of CPS1 deficiency, utilizing preclinical studies on analogous variants.
To date, the only CRISPR therapies authorized by the U.S. FDA have been for more prevalent conditions such as sickle cell disease and beta thalassemia, which affect tens of thousands or even hundreds of thousands of individuals. In KJ’s situation, his treatment was designed within six months post-birth, addressing his unique CPS1 variant. The team developed a base editing therapy that was administered via lipid nanoparticles to his liver to rectify the faulty enzyme.
The February administration marked the first of three doses; KJ received the subsequent two in March and April 2025. As of his last treatment, he has shown no significant adverse effects, demonstrates improved tolerance to dietary protein, and requires decreased medication to manage ammonia levels. While ongoing monitoring is necessary, Ahrens-Nicklas notes that the outcomes so far appear encouraging.
Ethical Implications of CRISPR
Like any pioneering technology, CRISPR presents intricate ethical